|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 14/755 | (2006.01) |
| (11) | Number of the document | 2956477 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14751254.5 |
| Date of filing the European patent application | 2014-02-14 | |
| (97) | Date of publication of the European application | 2015-12-23 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-18 |
| (46) | Date of publication of the claims translation | 2021-02-10 |
| (86) | Number | PCT/US2014/016441 |
| Date | 2014-02-14 |
| (87) | Number | WO 2014/127215 |
| Date | 2014-08-21 |
| (30) | Number | Date | Country code |
| 201361765626 P | 2013-02-15 | US |
| (72) |
TAN, Siyuan, US
PETERS, Robert, T., US
|
| (73) |
Bioverativ Therapeutics Inc.,
225 Second Avenue, Waltham, MA 02451,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Optimizuotas faktoriaus VIII genas |
| OPTIMIZED FACTOR VIII GENE |
| Payment date | Validity (years) | Amount | |
| 2024-12-20 | 12 | 289.00 EUR |
| 2026-02-14 |